Gilead Sciences Aktie: Lenacapavir als Hoffnungsträger
Analysten sehen in dem neuen HIV-Medikament Lenacapavir einen potenziellen Blockbuster, der die Umsätze des Biotechunternehmens deutlich steigern ... |
Updates & Legacy — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.